Oriptan (Sumatriptan)

Sumatriptan, the active ingredient in Oriptan, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. GNH USA supplies Oriptan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oriptan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oriptan belongs to the triptan class and is used to treat migraine-related conditions.

- Migraine with aura: Relieves headache pain and associated symptoms such as nausea and photophobia. - Migraine without aura: Reduces the severity and duration of migraine attacks. - Acute migraine treatment: Provides rapid relief when taken at the onset of migraine symptoms.

Side effects associated with Oriptan are generally mild to moderate and vary among individuals.

Common Side Effects: - Tingling sensation (paraesthesia) - Flushing - Warm‑up feeling - Dizziness - Fatigue - Nausea

Serious or Rare Side Effects: - Chest pain or pressure - Severe hypertension - Serotonin syndrome - Allergic reactions such as rash, itching, swelling - Cardiac arrhythmias - Ischemic events

When using Oriptan, certain      

-    t    t \\  \n  \